Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal

BSE2784.1011.3 (+0.41 %)

PREV CLOSE ( ) 2772.80

OPEN PRICE ( ) 2700.75

BID PRICE (QTY) 2784.10 (1)

OFFER PRICE (QTY) 2787.60 (2)

VOLUME 5236

TODAY'S LOW / HIGH ( )2700.75 2870.00

52 WK LOW / HIGH ( )2210 3645

NSE2771.40-3.9 (-0.14 %)

PREV CLOSE( ) 2775.30

OPEN PRICE ( ) 2739.00

BID PRICE (QTY) 2772.20 (5)

OFFER PRICE (QTY) 2773.90 (1)

VOLUME 123380

TODAY'S LOW / HIGH( ) 2725.00 2875.00

52 WK LOW / HIGH ( )2201.2 3653.95

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995

Management Info

Arvind Lal - Chairman - Managing Director

Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-30258600

Email lalpathlabs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details

MUFG Intime India Pvt Ltd.

Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi

Listing : BSE, NSE

NEWS

08May Dr. Lal PathLabs informs about press r
Dr. Lal PathLabs has informed that it attached copy of the Newspaper Adv..

26Apr Dr. Lal PathLabs informs about press r
Dr. Lal PathLabs has informed that it attached the copy of newspaper adv..

26Apr Dr. Lal PathLabs informs about newspap
Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Di..

25Apr Dr. Lal PathLabs informs about AGM
Dr. Lal PathLabs has informed that the Board of Directors in their meeti..

15Apr Dr. Lal PathLabs launches test for Amy
Dr. Lal PathLabs has introduced Amyloid typing by laser capture microdis..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	1484	4973
Gross Profit	1449	6213
Operating Profit	1843	7770
Net Sales	5772	23516

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr Agarwals Eye Hsp (BSE) 3996.05 (0.93%)	M.Cap ( in Cr)1896.47
Max Healthcare Inst (BSE) 1122.00 (1.05%)	M.Cap ( in Cr)108622.29
Thyrocare Tech. (BSE) 914.10 (0.71%)	M.Cap ( in Cr)4832.47
Kaya (BSE) 246.15 (1.80%)	M.Cap ( in Cr)324.30
Krsnaa Diagnostics (BSE) 709.55 (0.60%)	M.Cap ( in Cr)2291.12

Shareholding Pattern

	PROMOTERS	53.91%
	MUTUAL FUNDS/UTI	12.84%
	NON-INSTITUTION	6.1%
	FI/BANKS/INSURANCE	2.75%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
NJ ELSS Tax Saver S...	3.39
PGIM India Healthca...	2.25
Nippon India Pharma...	2.18
Quantum Ethical Fun...	2.14
DSP Nifty Smallcap2...	2.10
NJ Flexi Cap Fund-Reg(G)	2.00
Kotak Quant Fund-Reg(G)	1.78

Risk Disclosures on Derivatives

Smart Quotes

DR. LAL PATHLABS LTD.